Infections caused by Gram-positive bacteria: a review of the global challenge

Journal of Infection

Volumn 59, Issue SUPPL. 1, 2009, Pages

  Woodford, Neil ^a   Livermore, David M ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Antibiotic resistance; Enterococcus; Pneumococcus; Staphylococcus

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CARBAPENEM; CEFTAROLINE; CEFTOBIPROLE; CEPHALOSPORIN; CHLORAMPHENICOL; CIPROFLOXACIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; HABEKACIN; KETOLIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METICILLIN; MOXIFLOXACIN; ORITAVANCIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; TEICOPLANIN; TELAVANCIN; TELITHROMYCIN; TIGECYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; COMMUNICABLE DISEASE; ENTEROCOCCUS; EPIDEMIC; GENE MUTATION; GRAM POSITIVE INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOLECULAR CLONING; NONHUMAN; PREVALENCE; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MACROLIDES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PENICILLINS; PNEUMOCOCCAL INFECTIONS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 70249089650     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(09)60003-7     Document Type: Article

References (177)

1. Williams R.E. Epidemic staphylococci. Lancet 1 (1959) 190-195
2. Jevons M.P. "Celbenin"-resistant staphylococci. Br Med J 1 (1961) 124-125
3. Bogdanovich T., Ednie L.M., Shapiro S., and Appelbaum P.C. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother 49 (2005) 4210-4219
4. von Eiff C., Friedrich A.W., Becker K., and Peters G. Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes. Antimicrob Agents Chemother 49 (2005) 4372-4374
5. Chongtrakool P., Ito T., Ma X.X., Kondo Y., Trakulsomboon S., Tiensasitorn C., et al. Staphylococcal cassette chromosome mec (SCC mec) typing of methicillin-resistant Staphylococcus aureus strains isolated in 11 Asian countries: a proposal for a new nomenclature for SCCmec elements. Antimicrob Agents Chemother 50 (2006) 1001-1012
6. Zhang K., McClure J.A., Elsayed S., and Conly J.M. Novel staphylococcal cassette chromosome mec type, tentatively designated type VIII, harboring class A mec and type 4 ccr gene complexes in a Canadian epidemic strain of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53 (2009) 531-540
7. Deurenberg R.H., and Stobberingh E.E. The evolution of Staphylococcus aureus. Infect Genet Evol 8 (2008) 747-763
8. Hiramatsu K., Cui L., Kuroda M., and Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 9 (2001) 486-493
9. Oliveira D.C., Tomasz A., and De Lencastre H. The evolution of pandemic clones of methicillin-resistant Staphylococcus aureus: identification of two ancestral genetic backgrounds and the associated mec elements. Microb Drug Resist 7 (2001) 349-361
10. Oliveira D.C., Tomasz A., and De Lencastre H. Secrets of success of a human pathogen: molecular evolution of pandemic clones of meticillinresistant Staphylococcus aureus. Lancet Infect Dis 2 (2002) 180-189
11. Ito T., Ma X.X., Takeuchi F., Okuma K., Yuzawa H., and Hiramatsu K. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 48 (2004) 2637-2651
12. Hiramatsu K., Kondo N., and Ito T. Genetic basis for molecular epidemiology of MRSA. J Infect Chemother 2 (1996) 117-129
13. Huletsky A., Giroux R., Rossbach V., Gagnon M., Vaillancourt M., Bernier M., et al. New real-time PCR assay for rapid detection of methicillinresistant Staphylococcus aureus directly from specimens containing a mixture of staphylococci. J Clin Microbiol 42 (2004) 1875-1884
14. Huletsky A., Lebel P., Picard F.J., Bernier M., Gagnon M., Boucher N., et al. Identification of methicillin-resistant Staphylococcus aureus carriage in less than 1 hour during a hospital surveillance program. Clin Infect Dis 40 (2005) 976-981
15. Warren D.K., Liao R.S., Merz L.R., Eveland M., and Dunne Jr. W.M. Detection of methicillin-resistant Staphylococcus aureus directly from nasal swab specimens by a real-time PCR assay. J Clin Microbiol 42 (2004) 5578-5581
16. Wu S., Piscitelli C., De Lancastre H., and Tomasz A. Tracking the evolutionary origin of the methicillin resistance gene: cloning and sequencing of a homologue of mecA from a methicillin-susceptible strain of Staphylococcus sciuri. Microb Drug Resist 2 (1996) 435-441
17. Severin A., Wu S.W., Tabei K., and Tomasz A. High-level β-lactam resistance and cell wall synthesis catalyzed by the mecA homologue of Staphylococcus sciuri introduced into Staphylococcus aureus. J Bacteriol 187 (2005) 6651-6658
18. Enright M.C., Robinson D.A., Randle G., Feil E.J., Grundmann H., and Spratt B.G. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA). Proc Natl Acad Sci USA 99 (2002) 7687-7692
19. Deplano A., Tassios P.T., Glupczynski Y., Godfroid E., and Struelens M.J. In vivo deletion of the methicillin resistance mec region from the chromosome of Staphylococcus aureus strains. J Antimicrob Chemother 46 (2000) 617-620
20. Donnio P.Y., Oliveira D.C., Faria N.A., Wilhelm N., Le Coustumier A., and de Lencastre H. Partial excision of the chromosomal cassette containing the methicillin resistance determinant results in methicillin-susceptible Staphylococcus aureus. J Clin Microbiol 43 (2005) 4191-4193
21. Kerr S., Kerr G.E., Mackintosh C.A., and Marples R.R. A survey of methicillinresistant Staphylococcus aureus affecting patients in England and Wales. J Hosp Infect 16 (1990) 35-48
22. Zierdt C.H., Robertson E.A., Williams R.L., and MacLowry J.D. Computer analysis of Staphylococcus aureus phage typing data from 1957 to 1975, citing epidemiological trends and natural evolution within the phage typing system. Appl Environ Microbiol 39 (1980) 623-629
23. Richardson J.F., Chittasobhon N., and Marples R.R. Supplementary phages for the investigation of strains of methicillin-resistant Staphylococcus aureus. J Med Microbiol 25 (1988) 67-74
24. Walker J., Borrow R., Goering R.V., Egerton S., Fox A.J., and Oppenheim B.A. Subtyping of methicillin-resistant Staphylococcus aureus isolates from the North-West of England: a comparison of standardised pulsedfield gel electrophoresis with bacteriophage typing including an interlaboratory reproducibility study. J Med Microbiol 48 (1999) 297-301
25. McDougal L.K., Steward C.D., Killgore G.E., Chaitram J.M., McAllister S.K., and Tenover F.C. Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database. J Clin Microbiol 41 (2003) 5113-5120
26. Murchan S., Aucken H.M., O'neill G.L., Ganner M., and Cookson B.D. Emergence, spread, and characterization of phage variants of epidemic methicillinresistant Staphylococcus aureus 16 in England and Wales. J Clin Microbiol 42 (2004) 5154-5160
27. Enright M.C., Day N.P., Davies C.E., Peacock S.J., and Spratt B.G. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol 38 (2000) 1008-1015
28. Enright M.C., and Spratt B.G. Multilocus sequence typing. Trends Microbiol 7 (1999) 482-487
29. Johnson A.P., Aucken H.M., Cavendish S., Ganner M., Wale M.J., Warner M., et al. Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: Analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS). J Antimicrob Chemother 48 (2001) 143-144
30. Johnson A.P., Pearson A., and Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK. J Antimicrob Chemother 56 (2005) 455-462
31. Wannet W.J., Spalburg E., Heck M.E., Pluister G.N., Willems R.J., and de Neeling A.J. Widespread dissemination in The Netherlands of the epidemic Berlin methicillin-resistant Staphylococcus aureus clone with low-level resistance to oxacillin. J Clin Microbiol 42 (2004) 3077-3082
32. Wertheim H.F., Vos M.C., Boelens H.A., Voss A., Vandenbroucke-Grauls C.M., Meester M.H., et al. Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect 56 (2004) 321-325
33. Wulf M., and Voss A. MRSA in livestock animals an epidemic waiting to happen?. Clin Microbiol Infect 14 (2008) 519-521
34. van Belkum A., Melles D.C., Peeters J.K., Van Leeuwen W.B., van Duijkeren E., Huijsdens X.W., et al. Methicillin-resistant and -susceptible Staphylococcus aureus sequence type 398 in pigs and humans. Emerg Infect Dis 14 (2008) 479-483
35. Wulf M.W., Markestein A., van der Linden F.T., Voss A., Klaassen C., and Verduin C.M. First outbreak of methicillin-resistant Staphylococcus aureus ST398 in a Dutch hospital, June 2007. Euro Surveill 13 9 (2008). Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=8051 Published online February 28, 2008. Accessed March 13, 2009.
36. Draghi D.C., Sheehan D.J., Hogan P., and Sahm D.F. In vitro activity of linezolid against key Gram-positive organisms isolated in the United States: results of the LEADER 2004 surveillance program. Antimicrob Agents Chemother 49 (2005) 5024-5032
37. Jones R.N., Ross J.E., Castanheira M., and Mendes R.E. United States resistance surveillance results for linezolid (LEADER Program for 2007). Diagn Microbiol Infect Dis 62 (2008) 416-426
38. Weber J.T. Community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 41 Suppl 4 (2005) S269-S272
39. Zetola N., Francis J.S., Nuermberger E.L., and Bishai W.R. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 5 (2005) 275-286
40. Diederen B.M., and Kluytmans J.A. The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. J Infect 52 (2005) 157-168
41. Morgan M. Staphylococcus aureus, Panton-Valentine leukocidin, and necrotising pneumonia. Br Med J 331 (2005) 793-794
42. Vandenesch F., Naimi T., Enright M.C., Lina G., Nimmo G.R., Heffernan H., et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 9 (2003) 978-984
43. Robinson D.A., Kearns A.M., Holmes A., Morrison D., Grundmann H., Edwards G., et al. Re-emergence of early pandemic Staphylococcus aureus as a community-acquired meticillin-resistant clone. Lancet 365 (2005) 1256-1258
44. Tenover F.C., McDougal L.K., Goering R.V., Killgore G., Projan S.J., Patel J.B., et al. Characterization of a strain of community-associated methicillin-resistant Staphylococcus aureus widely disseminated in the United States. J Clin Microbiol 44 (2006) 108-118
45. Diep B.A., Gill S.R., Chang R.F., Phan T.H., Chen J.H., Davidson M.G., et al. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367 (2006) 731-739
46. Enright M.C. Genome of an epidemic community-acquired MRSA. Lancet 367 (2006) 705-706
47. Naas T., Fortineau N., Spicq C., Robert J., Jarlier V., and Nordmann P. Three-year survey of community-acquired methicillin-resistant Staphylococcus aureus producing Panton-Valentine leukocidin in a French university hospital. J Hosp Infect 61 (2005) 321-329
48. Kourbatova E.V., Halvosa J.S., King M.D., Ray S.M., White N., and Blumberg H.M. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections. Am J Infect Control 33 (2005) 385-391
49. Seybold U., Kourbatova E.V., Johnson J.G., Halvosa S.J., Wang Y.F., King M.D., et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis 42 (2006) 647-656
50. Roberts J.C., Cannons A.C., Amuso P.T., and Cattani J. Virtual digest identification of secondary enzymes for use in pulsed-field gel electrophoresis of Staphylococcus aureus. J Microbiol Methods 66 (2006) 362-368
51. Shopsin B., Gomez M., Montgomery S.O., Smith D.H., Waddington M., Dodge D.E., et al. Evaluation of protein A gene polymorphic region DNA sequencing for typing of Staphylococcus aureus strains. J Clin Microbiol 37 (1999) 3556-3563
52. Hiramatsu K., Hanaki H., Ino T., Yabuta K., Oguri T., and Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 40 (1997) 135-136
53. Ploy M.C., Grelaud C., Martin C., de Lumley L., and Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet 351 (1998) 1212
54. Martin R., and Wilcox K.R. Staphylococcus aureus with reduced susceptibility to vancomycin United States, 1997. MMWR Morb Mortal Wkly Rep 46 (1997) 765-766
55. Bierbaum G., Fuchs K., Lenz W., Szekat C., and Sahl H.-G. Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany. Eur J Clin Microbiol Infect Dis 18 (1999) 691-696
56. Cui L., Ma X., Sato K., Okuma K., Tenover F.C., Mamizuka E.M., et al. Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus. J Clin Microbiol 41 (2003) 5-14
57. Hanaki H., Labischinski H., Inaba Y., Kondo N., Murakami H., and Hiramatsu K. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimicrob Chemother 42 (1998) 315-320
58. Cui L., Murakami H., Kuwahara-Arai K., Hanaki H., and Hiramatsu K. Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicrob Agents Chemother 44 (2000) 2276-2285
59. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 1 (2001) 147-155
60. Wootton M., Avison M.B., Bennett P.M., Howe R.A., MacGowan A.P., and Walsh T.R. Genetic analysis of 17 genes in Staphylococcus aureus with reduced susceptibility to vancomycin (VISA) and heteroVISA. J Antimicrob Chemother 53 (2004) 406-407
61. Sakoulas G., Eliopoulos G.M., Moellering Jr. R.C., Wennersten C., Venkataraman L., Novick R.P., et al. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob Agents Chemother 46 (2002) 1492-1502
62. Cui L., Neoh H., Shoji M., and Hiramatsu K. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 53 (2009) 1231-1234
63. Sievert D.M., Boulton M.L., Stoltman G., Johnson D., Stobierski M.G., Downes F.P., et al. Staphylococcus aureus resistant to vancomycin United States, 2002. MMWR Morb Mortal Wkly Rep 51 (2002) 565-567
64. Sievert D.M., Rudrik J.T., Patel J.B., McDonald L.C., Wilkins M.J., and Hageman J.C. Vancomycin-resistant Staphylococcus aureus in the United States, 2002 2006. Clin Infect Dis 46 (2008) 668-674
65. Tenover F.C., Weigel L.M., Appelbaum P.C., McDougal L.K., Chaitram J., McAllister S., et al. Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania. Antimicrob Agents Chemother 48 (2004) 275-280
66. CDC. Vancomycin-resistant Staphylococcus aureus New York, 2004. MMWR Morb Mortal Wkly Rep 53 (2004) 322-323
67. Clark N.C., Weigel L.M., Patel J.B., and Tenover F.C. Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 49 (2005) 470-472
68. Perichon B., and Courvalin P. Heterologous expression of the enterococcal vanA operon in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 48 (2004) 4281-4285
69. Saha B., Singh A.K., Ghosh A., and Bal M. Identification and characterization of a vancomycin-resistant Staphylococcus aureus isolated from Kolkata (South Asia). J Med Microbiol 57 (2008) 72-79
70. Aligholi M., Emaneini M., Jabalameli F., Shahsavan S., Dabiri H., and Sedaght H. Emergence of high-level vancomycin-resistant Staphylococcus aureus in the Imam Khomeini Hospital in Tehran. Med Princ Pract 17 (2008) 432-434
71. Hope R., Livermore D.M., Brick G., Lillie M., Reynolds R., and on behalf of the BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001 06. J Antimicrob Chemother 62 Suppl 2 (2008) ii65-ii74
72. Murray B.E. The life and times of the enterococcus. Clin Microbiol Rev 3 (1990) 46-65
73. Moellering R.C.J. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother 28 (1991) 1-12
74. Carias L.L., Rudin S.D., Donskey C.J., and Rice L.B. Genetic linkage and cotransfer of a novel, vanB-containing transposon (Tn5382) and a low-affinity penicillin-binding protein 5 gene in a clinical vancomycin-resistant Enterococcus faecium isolate. J Bacteriol 180 (1998) 4426-4434
75. Rice L.B., Carias L.L., Rudin S., Lakticova V., Wood A., and Hutton-Thomas R. Enterococcus faecium low-affinity pbp5 is a transferable determinant. Antimicrob Agents Chemother 49 (2005) 5007-5012
76. Zscheck K.K., and Murray B.E. Nucleotide sequence of the β-lactamase gene from Enterococcus faecalis HH22 and its similarity to staphylococcal β-lactamase genes. Antimicrob Agents Chemother 35 (1991) 1736-1740
77. Murray B.E. β-Lactamase-producing enterococci. Antimicrob Agents Chemother 36 (1992) 2355-2359
78. Coudron P., Markowitz S.M., and Wong E.S. Isolation of a β-lactamase-producing, aminoglycoside-resistant strain of Enterococcus faecium. Antimicrob Agents Chemother 36 (1992) 1125-1126
79. Murray B.E., Church D.A., Wanger A., Zscheck K., Levison M.E., Ingerman M.J., et al. Comparison of two β-lactamase-producing strains of Streptococcus faecalis. Antimicrob Agents Chemother 30 (1986) 861-864
80. Murray B.E., An F.Y., and Clewell D.B. Plasmids and pheromone response of the β-lactamase producer Streptococcus (Enterococcus) faecalis HH22. Antimicrob Agents Chemother 32 (1988) 547-551
81. Rhinehart E., Smith N.E., Wennersten C., Gorss E., Freeman J., Eliopoulos G.M., et al. Rapid dissemination of β-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med 323 (1990) 814-818
82. Murray B.E., Singh K.V., Markowitz S.M., Lopardo H.A., Patterson J.E., Zervos M.J., et al. Evidence for clonal spread of a single strain of β-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J Infect Dis 163 (1991) 780-785
83. Patterson J.E., Singh K.V., and Murray B.E. Epidemiology of an epidemic strain of β-lactamase-producing Enterococcus faecalis. J Clin Microbiol 29 (1991) 2513-2516
84. Murray B.E., Lopardo H.A., Rubeglio E., Frosolono M., and Singh K.V. Intrahospital spread of a single gentamicin-resistant, β-lactamase-producing strain of Enterococcus faecalis in Argentina. Antimicrob Agents Chemother 36 (1992) 230-232
85. Rice L.B., Eliopoulos G.M., Wennersten C., Goldmann D., Jacoby G., and Moellering Jr. R.C. Chromosomally-mediated β-lactamase production and gentamicin resistance in Enterococcus faecalis. Antimicrob Agents Chemother 35 (1991) 272-276
86. Rice L.B., and Marshall S.H. Evidence of incorporation of the chromosomal β-lactamase gene of Enterococcus faecalis CH19 into a transposon derived from staphylococci. Antimicrob Agents Chemother 36 (1992) 1843-1846
87. Woodford N. Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci. Clin Microbiol Infect 11 Suppl 3 (2005) 2-21
88. Brown D.F.J., Hope R., Livermore D.M., Brick G., Broughton K., George R.C., et al. Non-susceptibility trends among enterococci and nonpneumococcal streptococci from bacteraemias in the UK and Ireland, 2001 06. J Antimicrob Chemother 62 Suppl 2 (2008) ii75-ii85
89. Werner G., Coque T.M., Hammerum A.M., Hope R., Hryniewicz W., Johnson A., et al. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 13 47 (2008). Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19046 Published online November 20, 2008. Accessed March 13, 2009.
90. Woodford N., Chadwick P.R., Morrison D., and Cookson B.D. Strains of glycopeptide-resistant Enterococcus faecium can alter their van genotypes during an outbreak. J Clin Microbiol 35 (1997) 2966-2968
91. Boyd D.A., Willey B.M., Fawcett D., Gillani N., and Mulvey M.R. Molecular characterization of Enterococcus faecalis N06-0364 with low-level vancomycin resistance harboring a novel D-Ala D-Ser gene cluster, vanL. Antimicrob Agents Chemother 52 (2008) 2667-2672
92. Woodford N. Novel agents for the treatment of resistant Gram-positive infections. Expert Opin Investig Drugs 12 (2003) 117-137
93. Akins R.L., and Rybak M.J. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 45 (2001) 454-459
94. Livermore D.M. Future directions with daptomycin. J Antimicrob Chemother 62 Suppl 3 (2008) iii41-iii49
95. Mercier R.C., Stumpo C., and Rybak M.J. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. J Antimicrob Chemother 50 (2002) 19-24
96. Pace J.L., and Judice J.K. Telavancin (Theravance). Curr Opin Investig Drugs 6 (2005) 216-225
97. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33 (1995) 2233-2239
98. Morrison D., Woodford N., Barrett S.P., Sisson P., and Cookson B.D. DNA banding pattern polymorphism in vancomycin-resistant Enterococcus faecium and criteria for defining strains. J Clin Microbiol 37 (1999) 1084-1091
99. Morrison D., Woodford N., and Cookson B.D. Epidemic vancomycin-resistant Enterococcus faecium in the UK. Clin Microbiol Infect 1 (1996) 146-147
100. Chadwick P., Oppenheim B.A., Fox A., Woodford N., Morgenstern G.R., and Scarffe J.H. Epidemiology of an outbreak due to glycopeptide-resistant Enterococcus faecium on a leukaemia unit. J Hosp Infect 34 (1996) 171-182
101. Nelson R.R., McGregor K.F., Brown A.R., Amyes S.G., and Young H. Isolation and characterization of glycopeptide-resistant enterococci from hospitalized patients over a 30-month period. J Clin Microbiol 38 (2000) 2112-2116
102. Woodford N., Reynolds R., Turton J., Scott F., Sinclair A., Williams A., et al. Two widely disseminated strains of Enterococcus faecalis highly resistant to gentamicin and ciprofloxacin from bacteraemias in the UK and Ireland. J Antimicrob Chemother 52 (2003) 711-714
103. Hallgren A., Saeedi B., Nilsson M., Monstein H.J., Isaksson B., Hanberger H., et al. Genetic relatedness among Enterococcus faecalis with transposon-mediated high-level gentamicin resistance in Swedish intensive care units. J Antimicrob Chemother 52 (2003) 162-167
104. Jett B.D., Huycke M.M., and Gilmore M.S. Virulence in enterococci. Clin Microbiol Rev 7 (1994) 462-478
105. Homan W.L., Tribe D., Poznanski S., Li M., Hogg G., Spalburg E., et al. Multilocus sequence typing scheme for Enterococcus faecium. J Clin Microbiol 40 (2002) 1963-1971
106. Ruiz-Garbajosa P, Nallapareddy SR, Murray BE, Bonten MJ, Top J, Coque T, et al. Enterococcus faecalis population structure. In: Proceedings & Abstracts of the 2nd International ASM FEMS Conference on Enterococci, Helsingør, Denmark; 2005, Abstract B4.
107. Willems R.J., Top J., van Santen M., Robinson D.A., Coque T.M., Baquero F., et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 11 (2005) 821-828
108. Leavis H.L., Willems R.J.L., Top J., and Bonten M.J.M. High-level ciprofloxacin resistance from point mutations in gyrA and parC confined to global hospital-adapted clonal lineage CC17 of Enterococcus faecium. J Clin Microbiol 44 (2006) 1059-1064
109. Farrell D.J., Felmingham D., Shackcloth J., Williams L., Maher K., Hope R., et al. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. J Antimicrob Chemother 62 Suppl 2 (2008) ii87-ii95
110. Jenkins S.G., Farrell D.J., Patel M., and Lavin B.S. Trends in anti-bacterial resistance among Streptococcus pneumoniae isolated in the USA, 2000 2003: PROTEKT US years 1 3. J Infect 51 (2005) 355-363
111. Jenkins S.G., Brown S.D., and Farrell D.J. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1 4. Ann Clin Microbiol Antimicrob 7 (2008) 1
112. McGee L., McDougal L., Zhou J., Spratt B.G., Tenover F.C., George R., et al. Nomenclature of major antimicrobial-resistant clones of Streptococcus pneumoniae defined by the pneumococcal molecular epidemiology network. J Clin Microbiol 39 (2001) 2565-2571
113. Bronzwaer S.L., Cars O., Buchholz U., Molstad S., Goettsch W., Veldhuijzen I.K., et al. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis 8 (2002) 278-282
114. Wise R. The relentless rise of resistance?. J Antimicrob Chemother 54 (2004) 306-310
115. Porat N., Barkai G., Jacobs M.R., Trefler R., and Dagan R. Four antibiotic-resistant Streptococcus pneumoniae clones unrelated to the pneumococcal conjugate vaccine serotypes, including 2 new serotypes, causing acute otitis media in southern Israel. J Infect Dis 189 (2004) 385-392
116. Dowson C.G., Hutchison A., Woodford N., Johnson A.P., George R.C., and Spratt B.G. Penicillin-resistant viridans streptococci have obtained altered penicillin-binding protein genes from penicillin-resistant strains of Streptococcus pneumoniae. Proc Natl Acad Sci USA 87 (1990) 5858-5862
117. Coffey T.J., Dowson C.G., Daniels M., and Spratt B.G. Horizontal spread of an altered penicillin-binding protein 2B gene between Streptococcus pneumoniae and Streptococcus oralis. FEMS Microbiol Lett 110 (1993) 335-339
118. Dowson C.G., Coffey T.J., Kell C., and Whiley R.A. Evolution of penicillin resistance in Streptococcus pneumoniae; the role of Streptococcus mitis in the formation of a low affinity PBP2B in S. pneumoniae. Mol Microbiol 9 (1993) 635-643
119. Beall B., McEllistrem M.C., Gertz Jr. R.E., Wedel S., Boxrud D.J., Gonzalez A.L., et al. Pre-and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol 44 (2006) 999-1017
120. Medina M.J., Greene C.M., Gertz R.E., Facklam R.R., Jagero G., Hamel M., et al. Novel antibiotic-resistant pneumococcal strains recovered from the upper respiratory tracts of HIV-infected adults and their children in Kisumu, Kenya. Microb Drug Resist 11 (2005) 9-17
121. Jefferies J.M.C., Smith A., Clarke S.C., Dowson C., and Mitchell T.J. Genetic analysis of diverse disease-causing pneumococci indicates high levels of diversity within serotypes and capsule switching. J Clin Microbiol 42 (2004) 5681-5688
122. Beall B., McEllistrem M.C., Gertz Jr. R.E., Boxrud D.J., Besser J.M., Harrison L.H., et al. Emergence of a novel penicillin-nonsusceptible, invasive serotype 35B clone of Streptococcus pneumoniae within the United States. J Infect Dis 186 (2002) 118-122
123. Henriqus N.B., Christensson B., Sandgren A., Noreen B., Sylvan S., Burman L.G., et al. Clonal analysis of Streptococcus pneumoniae nonsusceptible to penicillin at day-care centers with index cases, in a region with low incidence of resistance: emergence of an invasive type 35B clone among carriers. Microb Drug Resist 9 (2003) 337-344
124. Dagan R., and Klugman K.P. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis 8 (2008) 785-795
125. Van Valen L. A new evolutionary law. Evolutionary Theory 1 (1973) 1-30
126. Reynolds R., Potz N., Colman M., Williams A., Livermore D., and MacGowan A. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001 2002: the BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 53 (2004) 1018-1032
127. Tsiodras S., Gold H.S., Sakoulas G., Eliopoulos G.M., Wennersten C., Venkataraman L., et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 358 (2001) 207-208
128. Machado ARL, Andrade SS, Barth AL, Lutz L, Sader HS, Gales AC. The emergence of linezolid-resistance among Staphylococcus aureus from cystic fibrosis patients. In: Proceedings & Abstracts of the 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy, Chicago, IL. American Society for Microbiology; 2003, Abstract C2-1825.
129. Meka V.G., Pillai S.K., Sakoulas G., Wennersten C., Venkataraman L., DeGirolami P.C., et al. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA. J Infect Dis 190 (2004) 311-317
130. North S.E., Ellington M.J., Johnson A.P., Livermore D.M., and Woodford N. In vitro selection of linezolid resistance in hypermutable and wild-type Staphylococcus aureus. Clin Microbiol Infect 11 Suppl 2 (2005) 299 Abstract P974.
131. North SE, Ellington MJ, Johnson AP, Livermore DM, Woodford N. Chloramphenicol-selected mutants of Staphylococcus aureus may show cross-resistance to linezolid. In: Proceedings & Abstracts of the 45th Interscience Conference on Antimicrobial Agents & Chemotherapy, Washington, DC. American Society for Microbiology; 2005, Abstract C1-1417.
132. North SE, Ellington MJ, Johnson AP, Livermore DM, Woodford N. Novel pyrosequencing assays to detect T2500A and other mutations conferring linezolid resistance in Staphylococcus aureus. In: Proceedings & Abstracts of the 45th Interscience Conference on Antimicrobial Agents & Chemotherapy, Washington, DC. American Society for Microbiology; 2005, Abstract C2-272.
133. Wilson P., Andrews J.A., Charlesworth R., Walesby R., Singer M., Farrell D.J., et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 51 (2003) 186-188
134. Hill RLR, Kearns AM, Nash J, North SE, Pike R, Newson T, et al. Linezolid-resistant ST36 MRSA from two paediatric cystic fibrosis patients, following prolonged treatment. In: Proceedings & Abstracts of the 45th Interscience Conference on Antimicrobial Agents & Chemotherapy, Washington, DC. American Society for Microbiology; 2005, Abstract C2-273.
135. Fraimow HS, Knob C, Mazur W, McNutt S. Unsuspected emergence of linezolid resistance in coagulase negative staphylococci in a University Hospital. In: Proceedings & Abstracts of the 45th Interscience Conference on Antimicrobial Agents & Chemotherapy, Washington, DC. American Society for Microbiology; 2005, Abstract C2-271.
136. Zurenko GE, Todd WM, Hafkin B, Myers B, Kaufmann C, Bock J, et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid. In: Proceedings & Abstracts of the 39th Interscience Conference on Antimicrobial Agents & Chemotherapy, San Francisco, CA. American Society for Microbiology; 1999, Abstract 848.
137. Gonzales R.D., Schreckenberger P.C., Graham M.B., Kelkar S., DenBesten K., and Quinn J.P. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 357 (2001) 1179
138. Auckland C., Teare L., Cooke F., Kaufmann M.E., Warner M., Jones G., et al. Linezolid-resistant enterococci: report of the first isolates in the United Kingdom. J Antimicrob Chemother 50 (2002) 743-746
139. Johnson A.P., Tysall L., Stockdale M.W., Woodford N., Kaufmann M.E., Warner M., et al. Emerging linezolid resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 21 (2002) 751-754
140. Halle E., Padberg J., Rosseau S., Klare I., Werner G., and Witte W. Linezolid-resistant Enterococcus faecium and Enterococcus faecalis isolated from a septic patient: report of first isolates in Germany. Infection 32 (2004) 182-183
141. Herrero I.A., Issa N.C., and Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 346 (2002) 867-869
142. Engemann JJ, Joyce MJ, Harrell LJ, Evans SA, Reller LB, Sexton m DJ, et al. Outbreak of linezolid-resistant Enterococcus faecium bloodstream infections on an oncology ward. In: Proceedings & Abstracts of the 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy, Chicago, IL. American Society for Microbiology; 2003, Abstract K-1112.
143. Prystowsky J., Siddiqui F., Chosay J., Shinabarger D.L., Millichap J., Peterson L.R., et al. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 45 (2001) 2154-2156
144. Lobritz M., Hutton-Thomas R., Marshall S., and Rice L.B. Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis. Antimicrob Agents Chemother 47 (2003) 3318-3320
145. Marshall S.H., Donskey C.J., Hutton-Thomas R., Salata R.A., and Rice L.B. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob Agents Chemother 46 (2002) 3334-3336
146. Mazur W, Knob C, Fraimow HS. Quantification of 23S rRNA mutations and relative fitness of clinical isolates of linezolid-resistant Enterococcus faecalis. In: Proceedings & Abstracts of the 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy, San Diego, CA. American Society for Microbiology; 2002, Abstract C1-1607.
147. Sinclair A., Arnold C., and Woodford N. Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in enterococci. Antimicrob Agents Chemother 47 (2003) 3620-3622
148. Ruggero K.A., Schroeder L.K., Schreckenberger P.C., Mankin A.S., and Quinn J.P. Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 47 (2003) 511-513
149. Meka V.G., Gold H.S., Cooke A., Venkataraman L., Eliopoulos G.M., Moellering Jr. R.C., et al. Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus. J Antimicrob Chemother 54 (2004) 818-820
150. Wolter N., Smith A.M., Farrell D.J., Schaffner W., Moore M., Whitney C.G., et al. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob Agents Chemother 49 (2005) 3554-3557
151. Long K.S., Poehlsgaard J., Kehrenberg C., Schwarz S., and Vester B. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother 50 (2006) 2500-2505
152. Kehrenberg C., and Schwarz S. Distribution of florfenicol resistance genes fexA and cfr among chloramphenicol-resistant Staphylococcus isolates. Antimicrob Agents Chemother 50 (2006) 1156-1163
153. Kehrenberg C., Cuny C., Strommenger B., Schwarz S., and Witte W. Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr. Antimicrob Agents Chemother 53 (2009) 779-781
154. Toh S.M., Xiong L., Arias C.A., Villegas M.V., Lolans K., Quinn J., et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 64 (2007) 1506-1514
155. Mendes R.E., Deshpande L.M., Castanheira M., DiPersio J., Saubolle M.A., and Jones R.N. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother 52 (2008) 2244-2246
156. Cui L., Tominaga E., Neoh H., and Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50 (2006) 1079-1082
157. Camargo I., Neoh H., Cui L., and Hiramatsu K. Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob Agents Chemother 52 (2008) 4289-4299
158. Mangili A., Bica I., Snydman D.R., and Hamer D.H. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 40 (2005) 1058-1060
159. Hayden M.K., Rezai K., Hayes R.A., Lolans K., Quinn J.P., and Weinstein R.A. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43 (2005) 5285-5287
160. Vikram H.R., Havill N.L., Koeth L.M., and Boyce J.M. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol 43 (2005) 5384-5387
161. Marty F.M., Yeh W.W., Wennersten C.B., Venkataraman L., Albano E., Alyea E.P., et al. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J Clin Microbiol 44 (2006) 595-597
162. Skiest D.J. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44 (2006) 655-656
163. Sabol K., Patterson J.E., Lewis II J.S., Owens A., Cadena J., and Jorgensen J.H. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother 49 (2005) 1664-1665
164. Steenbergen J.N., Alder J., Thorne G.M., and Tally F.P. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother 55 (2005) 283-288
165. Hobbs J.K., Miller K., O'Neill A.J., and Chopra I. Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus. J Antimicrob Chemother 62 (2008) 1003-1008
166. D'Costa V.M., McGrann K.M., Hughes D.W., and Wright G.D. Sampling the antibiotic resistome. Science 311 (2006) 374-377
167. Werner G., Gfrorer S., Fleige C., Witte W., and Klare I. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother 61 (2008) 1182-1183
168. Johnson A.P., Sheppard C.L., Harnett S.J., Birtles A., Harrison T.G., Brenwald N.P., et al. Emergence of a fluoroquinolone-resistant strain of Streptococcus pneumoniae in England. J Antimicrob Chemother 52 (2003) 953-960
169. Ho P.L., Que T.L., Chiu S.S., Yung R.W., Ng T.K., Tsang D.N., et al. Fluoroquinolone and other antimicrobial resistance in invasive pneumococci, Hong Kong, 1995 2001. Emerg Infect Dis 10 (2004) 1250-1257
170. Farrell D.J., and Felmingham D. The PROTEKT global study (year 4) demonstrates a continued lack of resistance development to telithromycin in Streptococcus pneumoniae. J Antimicrob Chemother 56 (2005) 795-797
171. Rantala M., Haanpera-Heikkinen M., Lindgren M., Seppala H., Huovinen P., Jalava J., et al. Streptococcus pneumoniae isolates resistant to telithromycin. Antimicrob Agents Chemother 50 (2006) 1855-1858
172. Wilcox M.H. Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis. Best Pract Res Clin Gastroenterol 17 (2003) 475-493
173. Kuijper E.J., van Dissel J.T., and Wilcox M.H. Clostridium difficile: changing epidemiology and new treatment options. Curr Opin Infect Dis 20 (2007) 376-383
174. Kuijper E.J., Barbut F., Brazier J.S., Kleinkauf N., Eckmanns T., Lambert M.L., et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 13 31 (2008). Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18942 Published online July 31, 2008. Accessed March 13, 2009.
175. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 (2005) 1079-1084
176. McDonald L.C., Killgore G.E., Thompson A., Owens Jr. R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353 (2005) 2433-2441
177. Louie T.J. How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?. CMAJ 173 (2005) 1049-1050